MarketPulse
Z

$ZLDPY

4 articles found
3 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma

Zealand Pharma Plants U.S. Flag in Cambridge with $M Research Hub by 2026

Zealand Pharma opens Cambridge research hub in September 2026 to expand AI-driven drug discovery and develop next-generation hybrid molecule therapeutics.
ZLDPYDOCpeptide therapeuticsobesity
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Zealand Pharma Raises Capital Through Employee Warrant Exercise

Zealand Pharma raised DKK 955,071 through exercise of 10,530 employee warrants at DKK 90.70 per share, increasing total share capital to DKK 71,515,045.
ZLDPYcapital raisebiotechnology
GlobeNewswire Inc.GlobeNewswire Inc.··Roche

Roche's Weight-Loss Drug Shows Promise With Double-Digit Results in Phase II Trial

Roche's petrelintide demonstrates 10.7% weight reduction in Phase II, positioning the amylin analog as a potential alternative to dominant GLP-1 drugs with favorable tolerability. Phase III trials planned.
RHHBYZLDPYclinical resultsweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma

Zealand Pharma's Petrelintide Shows Promise in Obesity Drug Race

Zealand Pharma reports positive Phase 2 data for petrelintide, achieving 10.7% weight loss versus 1.7% placebo with favorable safety profile.
RHHBYZLDPYobesityweight management